rivastigmine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 65 Diseases   14 Trials   14 Trials   1875 News 


«12345678910111213...1617»
  • ||||||||||  Cognex (tacrine) / Shionogi
    Journal:  Phytochemicals-based Therapeutics against Alzheimer's Disease: An Update. (Pubmed Central) -  Nov 16, 2022   
    Phyto-chemicals derived from plants exhibit neuroprotection via targeting apoptosis, neurotrophic factor deficit, mitochondrial dysfunction, oxidative stress, and abnormal accumulation of proteins. Here, we discussed some of the neuroprotective phytochemicals used for the treatment of neurodegenerative diseases like AD and dementia.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    FDA event, Review, Journal:  Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer's Drugs. (Pubmed Central) -  Nov 15, 2022   
    As a result, the pharmacological therapeutic effectiveness is raised, while the unwanted side effects induced by the unspecific distribution decrease. This article reviews the recently developed DDSs to increase the efficacy of Food and Drug Administration-approved AD drugs.
  • ||||||||||  olanzapine / Generic mfg.
    Journal:  Case Series Profile of Olanzapine Post-Injection Delirium/Sedation Syndrome. (Pubmed Central) -  Nov 10, 2022   
    Olanzapine pamoate is an intramuscular depot injection for the treatment of schizophrenia...Most common treatment included supportive care without any pharmacological intervention (n=10), benzodiazepine (n=4) and benztropine (n=3)...In conclusion, this case series supports the characterisation of PDSS symptomology predominantly being anti-cholinergic with similar onset (<1 hour) and duration (<72hours). A combination of bromocriptine and physostigmine followed by rivastigmine is proposed to manage PDSS if patients develop severe dopamine blockade or anti-cholinergic delirium.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Journal:  Computationally Elucidating the Binding Kinetics for Different AChE Inhibitors to Access the Rationale for Improving the Drug Efficacy. (Pubmed Central) -  Oct 15, 2022   
    In addition, the binding kinetics of a drug may present different values in the proteins of different organisms because the residue compositions of the binding gorges of the targets are variant, that is, E2020 shows lower binding affinity and association energy barrier in binding with mAChE than TcAChE. However, HupA presents a better binding property with TcAChE than mAChE.
  • ||||||||||  rivastigmine / Generic mfg.
    Evaluation of the effects of dual-acting dapagliflozin in Alzheimer's disease induced rats (Poster area [IN-PERSON]) -  Oct 13, 2022 - Abstract #ECNP2022ECNP_970;    
    Adult female/male Sprague-Dawley rats were randomly divided into 5 groups: control (CON), Alzheimer's (ALZ), dapagliflozin (1 mg/kg) (ALZ+DAP), phlorizin (30 mg/kg) (ALZ+PHL), and rivastigmine (0.3 mg/kg) (ALZ+RIV) groups...Its enhancing effect on AD has also been demonstrated histopathological and immunohistochemically. In addition, according to molecular docking studies of SGLT inhibitors (1-2), they have been experimentally proven that AChE inhibition, as well as SGLT inhibition, can be beneficial in AD treatment together with other effects.
  • ||||||||||  rivastigmine / Generic mfg.
    Preclinical, Journal:  Neuroprotective Efficacy of Apple Cider Vinegar on Zinc-High Fat Diet-Induced Mono Amine Oxidase Alteration in Murine Model of AD. (Pubmed Central) -  Oct 12, 2022   
    In this experiment, out of five groups, three groups of animals were pretreated with one of the test drugs each i.e., Chrysin (10 mg/kg), ACV (0.7% v/v) and Rivastigmine (2.5 mg/kg) along with Zn with high fat diet (HFD) for 3 months and the rest two groups were that of control and disease induced...Amongst all three test drugs mentioned above, the ACV-treated group showed the most improvement during pretreatment. The findings suggest that ACV, might prove to be a beneficial nutraceutical & provide a protective effect against Alzheimer's disease (AD)-like neurological diseases.
  • ||||||||||  Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
    Onchocerciasis Drug Discovery - Evaluation of FDA-Approved Drugs against Onchocerca gutturosa in vitro. (Convention Center - Hall 4A (4th Floor); In-Person-Only) -  Oct 9, 2022 - Abstract #ASTMH2022ASTMH_2651;    
    Our results warrant further investigations regarding the possible re-purposing of some of the identified drugs. In addition, the identification of these hits may provide a good starting point for searches for related compounds of possible interest, and/or lead to new chemical synthesis.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Review:  Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review. (Pubmed Central) -  Oct 8, 2022   
    Short-term response may predict subsequent cognitive response, while higher education might correlate with short-term good response (months), and long-term poor response (years). Age, gender, baseline cognitive and functional levels, and APOE relationship with treatment outcome is controversial.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    TREATMENT STATUS OF ALZHEIMER’S DEMENTIA USING COMMON DATA MODEL IN SOUTH KOREA. () -  Oct 5, 2022 - Abstract #CTAD2022CTAD_181;    
    Age, gender, baseline cognitive and functional levels, and APOE relationship with treatment outcome is controversial. There were differences in persistence and the prescribing pattern among anti-dementia medications from database using the Observational Medical Outcome Partnership Common Data Model in South Korea.
  • ||||||||||  rivastigmine / Generic mfg.
    Rectal mass secondary to rectal ischemia: A case report () -  Oct 4, 2022 - Abstract #AGW2022AGW_523;    
    Acute rectal ischemia is rare, and, because of its extensive collateral blood supply, the ischemic change could initially mimic a rectal mass. Histopathological diagnosis is crucial.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Differential neuroprotective effect of curcuminoid formulations in aluminum chloride-induced Alzheimer's disease. (Pubmed Central) -  Sep 29, 2022   
    Experimental rodents were administered with AlCl (300 mg/kg) to induce AD and treated with rivastigmine, curcuminoid crude extract, CRE, and TC orally for three consecutive weeks...CRE and TC supplementation remarkably downregulated the interleukin-1α, tumor necrosis factor-α, interleukin-1β, acetylcholinesterase, and β-secretase pathological gene expression. Hence, it was concluded that CRE and TC may act as promising candidates in the prevention of AD via numerous underlying signaling pathways.
  • ||||||||||  rivastigmine / Generic mfg., quetiapine / Generic mfg.
    Post deep brain stimulation cognitive decline in GBA-related Parkinson’s disease (Poster Station: 10) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1299;    
    While the motor benefit of STN-DBS in GBA-PD is lasting, continuous cognitive deterioration is expected. The question if DBS-STN accelerate the cognitive deterioration in GBA-PD is still open and therefore, until additional data is accumulated this procedure should not be avoided for GBA-PD patients with significant motor fluctuations
  • ||||||||||  rivastigmine / Generic mfg., duloxetine / Generic mfg.
    ASYMMETRIC EARLY-ONSET PARKINSONISM DUE TO PSEN1 MUTATION (Poster Station: 14) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_604;    
    Parkinsonism in a young adult may be an uncommon presentation of a PSEN1 mutation. Therefore, PSEN1 gene should be considered in the genetic panel for early-onset Parkinson’s disease.
  • ||||||||||  carbidopa/levodopa / Generic mfg., rivastigmine / Generic mfg.
    Spinocerebellar ataxia 21 and phenotypic variability within a family (Poster Station: 2) -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_409;    
    Therefore, PSEN1 gene should be considered in the genetic panel for early-onset Parkinson’s disease. SCA21 is a slowly progressive autosomal dominant spinocerebellar ataxia with variable neurodevelopmental phenotypes including multiple movement disorders within the same variant.
  • ||||||||||  Aduhelm (aducanumab) / Eisai, Biogen, Nine Phase One (mannote sodium) / Shanghai Greenvalley
    Review, Journal:  Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. (Pubmed Central) -  Sep 3, 2022   
    Small molecules, mAbs, or multimodal strategies showing promise in animal studies have not confirmed that promise in the clinic (where small to moderate changes in clinical efficacy have been observed), and therefore, there is a significant unmet need for a better understanding of the AD pathogenesis and the exploration of alternative etiologies and therapeutic effective disease-modifying therapies strategies for AD. Therefore, a critical review of the disease-modifying therapy pipeline for Alzheimer's disease is needed.
  • ||||||||||  An Evaluation of Health Technology Assessment (HTA) Requirements for Emerging Therapies in Alzheimer’s Disease (AD) (In-person; Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_756;    
    Then we mapped the identified requirements from the HTA reports with endpoints used in clinical trials of emerging therapies (identified through clinicaltrials.gov), namely aducanumab, donanemab, gantenerumab, and lecanemab...Donepezil, galantamine, rivastigmine, and memantine are reimbursed in Germany, England, and Wales but not in France... Although clinical trials on new AD agents include HTA- and payer-relevant endpoints, it is highly recommended to also assess time to institutionalisation, HRQoL, and caregiver burden to generate a compelling HTA and payer evidence package.
  • ||||||||||  Journal:  Drugs for cognitive loss and dementia. (Pubmed Central) -  Aug 28, 2022   
    These results suggest the potentiality provided by rivastigmine tartrate-loaded solid lipid nanoparticles for nasal delivery. No abstract available
  • ||||||||||  Aduhelm (aducanumab) / Eisai, Biogen, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma, Adlarity (donepezil transdermal system) / Corium
    Journal:  Comparison table: Drugs for Alzheimer's disease. (Pubmed Central) -  Aug 28, 2022   
    No abstract available No abstract available
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Review, Journal:  Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology. (Pubmed Central) -  Aug 22, 2022   
    We have discussed pathophysiology, various targets, FDA-approved drugs, and various drugs in clinical trials against AD. The goal of this study is to shed light on current developments and treatment options, utilizing phytopharmaceuticals, nanomedicines, nutraceuticals, and gene therapy.
  • ||||||||||  galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Isatin-linked heterocycles for inhibition of acetylcholinesterase and butyrylcholinesterase | Poster Board #2769 (Hall F2 (McCormick Place Convention Center)) -  Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_12928;    
    This series of molecules shows selective inhibition of butyrylcholinesterase (BChE) with low micromolar IC50 values. Subsequent studies are exploring the SAR and mode of interaction of these selective compounds with BChE, and additional synthetic and enzymatic inhibition results of these ongoing studies will be presented.
  • ||||||||||  rivastigmine / Generic mfg.
    Modular mimics of neuroactive alkaloids: Design, synthesis, cholinesterase inhibitory activity, and sterics study of novel rivastigmine analogs | Poster Board #2703 (Hall F2 (McCormick Place Convention Center)) -  Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_1254;    
    The research in our group focused on the synthetic optimization of rivastigmine and its analogs, utilizing computer modeling and biological assays to determine the most favorable analog for inhibition of acetylcholinesterase (AChE). Through such studies, it was determined that rivastigmine and its analogs were less effective at inhibiting AChE than physostigmine, and their biological activity is governed by sterics, prompting us to pursue three routes: the synthesis of S-enantiopure versions of our analogs, the synthesis of analogs with less steric hindrance, and the study of biological activity for all analogs on both cholinesterase enzymes to determine enzyme selectivity.
  • ||||||||||  rivastigmine / Generic mfg.
    Biomarker, Journal:  Downregulation of serum miR-106b: a potential biomarker for Alzheimer disease. (Pubmed Central) -  Aug 5, 2022   
    In this study, we investigated the serum levels of miR-106b as a diagnostic biomarker for AD and evaluate its predictive value for therapeutic response to the drug rivastigmine...The serum values of miR-106b tended to be positively associated with the therapeutic response but were not significant (p = .15). Taken together, detection of serum miR-106b might be a promising serum biomarker for early diagnosis of AD.